ANEBULO PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.87 per share for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-09-29
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-09-30 was $1.99, a 18.11% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-09-30 was $2.43.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.87, a 50.29% decline from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.75, a 5.91% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.86.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $0.11.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.87 10-K · filed 2025-09-29 | |||
| 2025-03-31 | $1.12 10-Q · filed 2025-05-13 | |||
| 2024-06-30 | $1.75 10-K · filed 2025-09-29 | |||
| 2024-03-31 | $1.83 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $1.85 10-Q · filed 2024-02-13 | |||
| 2023-09-30 | $1.99 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $1.86 10-K · filed 2024-09-25 | |||
| 2023-03-31 | $1.86 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $1.86 10-Q · filed 2023-02-10 | |||
| 2022-09-30 | $2.43 10-Q · filed 2022-11-10 | |||
| 2022-03-31 | $3.07 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $2.39 10-Q · filed 2022-02-11 | |||
| 2021-06-30 | $0.11 10-K · filed 2022-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |